DUPUYTREN LITERATURE: INTERLEUKIN 1 RECEPTOR ANTAGONIST
These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.
Selected Publications
- Brown CA, Toth AP, Magnussen B (2010) Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics 33, 877. (PDF)
- Bujak M, Ratkaj I, Markova-Car E et al. (2015) Inflammatory Gene Expression Upon TGF-ß1-Induced p38 Activation in Primary Dupuytren’s Disease Fibroblasts. Frontiers in Molecular Biosciences 2, 1–9. (PDF)
- Dixon D, Coates J, Del Carpio Pons A et al. (2015) A potential mode of action for Anakinra in patients with arthrofibrosis following total knee arthroplasty. Scientific Reports 5, 1–10. (PDF)
- Kallianos S, Singh V, Henry D, Berkoff D, Dahners L, Weinhold P (2017) Interleukin 1-Receptor Antagonist Inhibits Arthrofibrosis in a Post-Traumatic Knee Immobilization Model. ORS 2017 Annual Meeting Poster No.1506, 2017. (PDF)
- Omoigui S, Irene S (2004) Subcutaneous injection of anakinra in patients with shoulder pain due to rotator cuff tendonitis and subacromial bursitis. Pain medicine 5, 229–30. (PDF)
- Rosenthal AK, Ryan LM (2014) Nonpharmacologic and pharmacologic management of CPP crystal arthritis and BCP arthropathy and periarticular syndromes. Rheumatic Disease Clinics of North America 40, 343–356. (PDF)
- Zufferey P, So A (2012) A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder. Annals of the Rheumatic Diseases 72, 465–467. (PDF)
